SAO PAULO, July 26 (Reuters) - China National Pharmaceutical
Group Co Ltd (Sinopharm) has applied for emergency
use authorization for its COVID-19 vaccine in Brazil, the
Brazilian health agency Anvisa said in a statement on Monday.
Brazil already uses another Chinese COVID-19 vaccine,
Sinovac Biotech's Coronavac, which is the vaccine most
administered in the South American nation.
Sinopharm's vaccine is made from an inactivated virus,
Anvisa said, and is recommended for people over age 18. The
agency added that it is applied in two doses, with an interval
of three to four weeks between them, citing information provided
by the manufacturer.
The agency said that it will review over the next day
whether the documentation submitted by Sinopharm is complete and
that it may request additional information to process the
(Reporting by Anthony Boadle
Writing by Ana Mano
Editing by Jonathan Oatis and Will Dunham)